Amneal Pharmaceuticals, Inc. Q4 2025 Earnings Call Summary

1Key Financial Results and Metrics

Q4 2025 Performance::

Revenues: $814 million, up 11% year-over-year.

Adjusted EBITDA: $175 million, a 13% increase.

Adjusted EPS: $0.21, reflecting a 75% growth.

Full Year 2025 Performance::

Total Revenue: $3 billion, an 8% increase.

Adjusted EBITDA: $688 million, up 10%.

Adjusted EPS: $0.83, a 43% increase.

Operating Cash Flow: $340 million.

Net Leverage: Reduced to 3.5x from 7.4x in 2019.

2Strategic Updates and Business Highlights

Affordable Medicines Segment::

Revenue growth expected to accelerate in 2026 and 2027, driven by a robust pipeline of complex generics and injectables.

Launched significant products including risperidone extended release and multiple injectables.

Specialty Segment::

Krexone achieved a 3% market share with 23,000 patients one year post-launch; expected to double market share in 2026.

New product Breqia launched for migraine treatment.

Biosimilars::

Received approval for adenosuba biosimilars, with plans to have six biosimilars in the U.S. market by 2027.

Xolair biosimilar anticipated to be a significant revenue driver starting in 2026.

Collaboration with Pfizer::

Progressing well in the GLP-1 obesity treatment partnership, with manufacturing facilities on track.

3Forward Guidance and Outlook

2026 Guidance::

Expected revenue growth of 1% to 4%, with total revenue projected between $3.05 billion and $3.15 billion.

Adjusted EBITDA growth anticipated between 5% and 10%.

Adjusted EPS forecasted to be between $0.93 and $1.03, reflecting 12% to 20% growth.

Operating cash flow expected between $325 million and $375 million.

4Bad News, Challenges, or Points of Concern

Affordable Medicines Segment::

Revenue was flat in Q4, reflecting timing of product launches.

AvKARE Segment::

Expected revenue decline in 2026 due to loss of exclusivity on key products and a strategic pivot away from low-margin distribution business.

Specialty Segment::

Anticipated flat revenue in 2026 due to generic erosion of Rytary, although growth is expected to resume in 2027.

5Notable Q&A Insights

Krexone Market Performance::

Strong uptake with 80% of patients converting from immediate-release therapies; aiming for a first-line therapy status.

Biosimilars and Competition::

Xolair expected to capture a significant share of the market quickly due to established relationships with large buying groups.

Omnipaque Opportunity::

Anticipated limited competition due to complex manufacturing and supply chain challenges; additional strengths expected to be approved by year-end 2026. Overall, Amneal Pharmaceuticals demonstrated strong financial performance in 2025, with a diversified portfolio and strategic initiatives poised for growth. However, challenges in specific segments and anticipated revenue declines in 2026 highlight the need for careful navigation of market dynamics.